BioSpace News Archive

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 6, 2020 to discuss its third quarter operating results.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 11, 2020.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury® (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization.

RNA sequencing and novel machine learning algorithms generate a test that improves lung cancer diagnosis using brushings from the main lung airway

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance marketplace, announces today its financial results for the third quarter ended September 30, 2020.

- KBP Biosciences Holdings Limited (KBP Biosciences), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting, being held in a virtual format from October 22-25, 2020. Frederic Jaisser, Head of the Physiology

Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that that it has closed an expansion of its Series A financing. As part of this expanded financing, Abingworth LLP has joined the existing Series A investors led by Longitude Capital, H.I.G. BioVentures and Adams Street Partners. In conjunction with the financing, Kur

Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune excluded solid tumors, aspects that immune checkpoint inhibitors do not address. - Preclinical Proof of Concept for Company’s priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine re

KB-0742 is a transcription regulatory network modulator discovered using the company’s proprietary high - throughput screening platform Research s howed KB-0742 i nhibited a ndrogen r eceptor -d ependent a ctivity and r educed t umor g rowth in c astration -r esistant p rostate c ancer Company is on t rack to s ubmit an IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2020 on Monday, November 2 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the third quarter